Gleiss Lutz has advised the shareholders of the TTP Group – Robus Capital Management, ABAG Börsebius Holding AG and Dr. Bonhoff GmbH – on the sale of their shares to Exyte GmbH.
The financial investor Robus Capital and the minority shareholders of TTP signed corresponding agreements with Exyte, a global leader in the design, engineering and delivery of high-tech facilities, on 4 September 2024. The parties have agreed not to disclose the purchase price. Closing is expected to take place in October, subject to the necessary regulatory approvals.
The TTP Group is a leading consulting and engineering firm for the pharmaceutical and chemical industries in Europe. Operating under the brands Pharmaplan and Triplan, it serves blue-chip clients at 27 locations across Europe and has around 1,000 employees.
The following Gleiss Lutz team advised the shareholders of the TTP Group: Dr. Andreas Löhdefink (partner), Dr. Christoph Auchter (both lead), Dr. Ken Laws (all M&A), Dr. Ocka Stumm (partner), Dr. Dominik Monz, Kilian Mossel (all Tax), Dr. Alexander Fritzsche (partner, all Frankfurt), Dr. Christina Wolf (both Competition/Antitrust, Brussels), Dr. Kai Arne Birke (partner), Dr. Jan-Alexander Lange (counsel, both Banking & Finance, both Frankfurt).
Forward
